Cureus
January 31, 2026
Lukasz Siwek, Marta Nowocien, Barbara Balajewicz et al.
Psilocybin is a psychoactive chemical compound that exerts its effects through the activation of serotonergic receptors. It occurs naturally in mushrooms of the genus Psilocybe. Despite its potential medical applications, this substance is regarded as a drug with no recognized medical use. Depression constitutes a psychiatric disorder of substantial global burden, affecting millions of...
International Journal of Innovative Technologies in Social Science
January 28, 2026
Łukasz Deska, Cezary Kosmecki, Dawid Głaz et al.
This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synthesis of academic literature, drawing...
Quality in Sport
January 26, 2026
Adam Wolski, Ewa Szplit, Mikołaj Franciszek Patalong et al.
Background: Psychedelic substances have been used for millennia in religious and healing contexts and have recently re-emerged as subjects of scientific interest due to advances in neuroscience and psychiatry. Research suggests that psychedelics may address limitations of conventional psychiatric treatments, particularly in disorders such as major depressive disorder, PTSD, substance use...
Zenodo (CERN European Organization for Nuclear Research)
January 26, 2026
Fernando Mora López, Johynny Solís Solís, Ekaterina Daniela Hernández Baker et al.
preprint
This review examines the therapeutic efficacy of psilocybin for major depressive disorder by integrating findings from clinical trials, meta-analyses, and mechanistic research. A comprehensive literature search across major scientific databases identified empirical studies evaluating psilocybin’s effects on depressive symptomatology, safety, and underlying neurobiological mechanisms....
Emerging Minds Journal for Student Research
January 25, 2026
Rishika Scott, James Smith
Treatment-resistant depression (TRD) has been well-researched within scientific literature, although the therapeutic value of psilocybin is not fully understood. The aim of this systematic review is to determine a stable and effective dosage unit to inform health professionals of the benefits of psilocybin, using peer-reviewed literature and meta-analysis. The review will also compare selective...
Neuroscience & Biobehavioral Reviews
January 24, 2026
Omer A. Syed, Benjamin Tsang, Sean M. Nestor et al.
Psilocybin-assisted therapy (PAT) is an emerging intervention for depression. Though several clinical trials report promising results for PAT in treating depression, there remains a need for consensus on optimal methodologies and standardization of PAT protocols. The objective of this review was to assess the efficacy of PAT in treating depressive symptoms and to systematically examine the...
Zenodo (CERN European Organization for Nuclear Research)
January 22, 2026
preprint
Psilocybin therapy shows potential benefits for mental health conditions such as depression and substance use disorders, though further research is needed to confirm long-term safety and efficacy.
Neuropharmacology
January 21, 2026
Ana Domi, Erika Lucente, Davide Cadeddu et al.
1 citation
Psilocybin is a naturally occurring psychedelic compound with potential antidepressant effects. Although it has long been used by humans, primarily for recreational purposes, the molecular mechanisms underlying its actions remain incompletely understood. Here, we examined the acute effects of psilocin, the active metabolite of psilocybin, on excitatory neurotransmission in the prefrontal cortex...
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
January 20, 2026
Ke Xia, Tianming Gao
Depression is a complex and globally prevalent mental disorder, for which conventional antidepressant medications face limitations such as delayed onset and insufficient efficacy. Classic psychedelics, most notably psilocybin, have recently emerged as promising candidates for treatment of depression and demonstrated rapid, robust, and sustained antidepressant effects in controlled clinical...
Psychedelic Medicine
January 18, 2026
Anthony L. Back, Bonnie A. Mcgregor, Leslie Lazar Thorn et al.
1 citation
Background: Psilocybin is a promising therapy for cancer-related distress, but existing individual treatment models are resource intensive. In this study, we designed and tested a group model of psilocybin therapy for people with metastatic cancer and cancer-related anxiety and depression. Method: Eligibility criteria included metastatic cancer, moderate-to-severe symptoms of anxiety or...